Abstract 568P
Background
Testing for DNA mismatch repair deficiency (MMRd) is recommended for all colorectal cancers (CRC). Automation of this would facilitate precision medicine, particularly if it provided information on likely aetiology.
Methods
We developed AIMMer, an AI-based method for determination of MMR protein expression at single cell level from IHC-stained routine pathology samples. We applied it to over 2,000 cases from the SCOT clinical trial, which compared 3 vs 6 months of oxaliplatin-based adjuvant chemotherapy (mFOLFOX6 or CAPOX) for stage II/III CRC. AIMMer performance was evaluated against ground truth established by blinded review by two expert pathologists, and MMRd prognostic and predictive value was determined by Cox proportional hazards models.
Results
Benchmarking of AIMMeR against pathologist ground truth MMR calls revealed AUROC of 0.98 (bootstrap 95% CI = 0.97–0.99) and Youden index (sensitivity plus specificity) of 1.87 at cutpoint of 10.7% MMR positive cells. This cutpoint gave positive predictive value (PPV) of >95% for both the commonest pattern of somatic MMRd (MLH1 and PMS2 loss) and for MMR proficient (MMRp) status, and agreement with pathologist calls approaching that between individual pathologists (k = 0.79–0.82 vs 0.88). Analysis of CRC recurrence-free interval (RFI) confirmed MMRd prognostic value in oxaliplatin-treated patients (multivariable-adjusted HR (aHR) = 0.62, 95% CI = 0.44–0.88, P=0.007), with effect size larger in those <70 years and those with right-sided tumours. MMRd did not predict differential benefit from chemotherapy duration. Patients with MMRp tumors had similar RFI whether treated with CAPOX or FOLFOX (aHR = 0.95, 95% CI= 0.77-1.16, P=0.6), while those with MMRd tumours treated with FOLFOX had shorter RFI (aHR = 2.08, 95% CI= 1.09-3.97, P=0.027, P INTERACTION=0.04).
Conclusions
AIMMeR holds promise to reduce pathologist workflow and streamline clinical diagnostics in CRC. The possible predictive value of MMRd for chemotherapy regimen should be investigated in additional cohorts.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
D.N. Church.
Funding
Cancer Research UK, National Institute for Health Research (NIHR), Promedica.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
548P - Diffuse midline gliomas H3K27-altered in adults, the experience of an oncology center
Presenter: Carolina Trabulo
Session: Poster session 10
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10
570P - Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Presenter: Kui Wu
Session: Poster session 10